Cisplatin Plus Etoposide in the Adjuvant Treatment of Patients with Non-Small Cell Lung Cancer | Zendy

Erdem Çubukçu | Zendy; Mustafa Canhoroz | Zendy; Ömer Fatih Ölmez | Zendy; Özkan Kanat | Zendy; Ender Kurt | Zendy; Muharrem Erol | Zendy; Sinem Çubukçu | Zendy; Nadide Yorulmaz | Zendy; Ahmet Sami Bayram | Zendy; Türkkan Evrensel | Zendy; Osman Manavoğlu | Zendy; Tıbbi Onkoloji | Zendy; Bilim Dalı | Zendy; İç Hastalıkları | Zendy; Anabilim Dalı | Zendy; Küçük Hücreli | Zendy; Dışı Akciğer | Zendy; Kanseri Hastalarının | Zendy; Hücreli Küçük | Zendy; Akciger Dışı | Zendy; Adjuvan Kanseri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cisplatin Plus Etoposide in the Adjuvant Treatment of Patients with Non-Small Cell Lung Cancer

Author(s) -

Erdem Çubukçu,

Mustafa Canhoroz,

Ömer Fatih Ölmez,

Özkan Kanat,

Ender Kurt,

Muharrem Erol,

Sinem Çubukçu,

Nadide Yorulmaz,

Ahmet Sami Bayram,

Türkkan Evrensel,

Osman Manavoğlu,

Tıbbi Onkoloji,

Bilim Dalı,

İç Hastalıkları,

Anabilim Dalı,

Küçük Hücreli,

Dışı Akciğer,

Kanseri Hastalarının,

Hücreli Küçük,

Akciger Dışı,

Adjuvan Kanseri

Publication year - 2014

Publication title -

the annals of clinical and analytical medicine

Language(s) - English

Resource type - Journals

ISSN - 2667-663X

DOI - 10.4328/jcam.1469

Subject(s) - medicine , etoposide , cisplatin , adjuvant , lung cancer , oncology , adjuvant chemotherapy , chemotherapy , pharmacology , cancer , breast cancer

Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research